Anne-Françoise Dillies

Author

Centre Jean Perrin

Also Known As

A. Dillies, A.-F. Dillies, A.F. Dillies, Anne-Francoise Dillies, Anne-Françoise Dillies

Publications

1.1K

Citations

H-Index

Concepts

All Affiliations

Centre Jean Perrin Centre Léon Bérard Université Clermont Auvergne Centre Hospitalier Universitaire de Clermont-Ferrand Centre Georges François Leclerc

About

Anne-Françoise Dillies is an author at Centre Jean Perrin specializing in medicine, radiation oncology, and head and neck cancer.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	6	6	1K
2	Health Sciences	4	4	343
3	Epidemiology	1	1	556
4	Immunology	1	1	77
5	Microbiology	1	1	556

Anne-Françoise Dillies

Publications

1.1K

Citations

H-Index

Page 1

	Year	Citations
Clinical features and prognostic factors of listeriosis: the MONALISA national prospective cohort study Caroline Charlier, Élodie Perrodeau, Alexandre Leclercq, The Lancet Infectious Diseases Prognostic FactorsFoodborne IllnessClinical FeaturesMicrobiologyInfection Control	2017	556
Phase II Study of Sunitinib in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck: GORTEC 2006-01 Jean‐Pascal Machiels, Stéphanie Henry, Sylvie Zanetta, Journal of Clinical Oncology Oncologic ImagingSunitinib MonotherapyDce-mri MonitoringMedicinePhase Ii Study	2009	169
Cetuximab, docetaxel, and cisplatin as first-line treatment in patients with recurrent or metastatic head and neck squamous cell carcinoma: a multicenter, phase II GORTEC study J. Guigay, Jérôme Fayette, Anne-Françoise Dillies, Annals of Oncology Neoadjuvant TherapyMedicinePathologyFirst-line TreatmentHead And Neck Cancer	2015	145
Immunonutrition improves functional capacities in head and neck and esophageal cancer patients undergoing radiochemotherapy: A randomized clinical trial M.-P. Vasson, Jérémie Talvas, Olivier Perche, Clinical Nutrition Randomized Clinical TrialEsophageal Cancer PatientsFunctional CapacitiesEsophageal CancerRadiation Therapy	2013	77
NISCAHN: A phase II, multicenter nonrandomized trial aiming at evaluating nivolumab (N) in two cohorts of patients (pts) with recurrent/metastatic (R/M) salivary gland carcinoma of the head and neck (SGCHN), on behalf of the Unicancer Head & Neck Group. Jérôme Fayette, Caroline Even, Laurence Digue, Journal of Clinical Oncology Non-acc PtsPhase IiNeck GroupPrimary EndpointMedicine	2019	58
Cetuximab, docetaxel, and cisplatin (TPEx) as first-line treatment in patients with recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN): Final results of phase II trial GORTEC 2008-03. J. Guigay, Jérôme Fayette, Anne-Françoise Dillies, Journal of Clinical Oncology Squamous Cell CarcinomaPathologyFirst-line TreatmentPharmacotherapyOncology	2012	39
Predictive factors of toxicity of TPF induction chemotherapy for locally advanced head and neck cancers Maureen Bernadach, M. Lapeyre, Anne-Françoise Dillies, BMC Cancer	2021	28
Adherence with Oral Oncologic Treatment in Cancer Patients: Interest of an Adherence Score of All Dosing Errors Émilie Thivat, Isabelle Van Praagh, A. Bellière, Oncology	2012	21
Will the presence of the patient at multidisciplinary meetings influence the decision in head and neck oncology management? J. Massoubre, M. Lapeyre, R. Pastourel, Acta Oto-Laryngologica	2017	12

Page 1